XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis

Jerry Y.  Tan Chun Bing; Andrew A.  Yacat; Dennis L.  Sacdalan

doi:10.47895/amp.v49i2.988

XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis

Jerry Y. Tan Chun Bing
Andrew A. Yacat
Dennis L. Sacdalan

DOI:

https://doi.org/10.47895/amp.v49i2.988

Abstract

...

References

How to Cite

XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. Acta Med Philipp [Internet]. 2015 Jun. 30 [cited 2026 Jul. 28];49(2). Available from: https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/988

Most read articles by the same author(s)

Nelson A. Laja, Arthur Gregory A. Lui, Joar Kent P. Gumapon, Corazon A. Ngelangel, Anna Melissa S. Guerrero, Dennis L. Sacdalan, Rachel Marie B. Rosario, Romeo V. Marcaida, Immunohistochemical Profile, Pattern of Recurrence, and Time to Progression of Non-Metastatic Breast Cancer Patients of the Department of Health-Breast Cancer Medicines Access Program , Acta Medica Philippina: Vol. 49 No. 2 (2015)
Ivy D. de Dios, Jerry Y. Tan Chun Bing, Susano B. Tanael, Corazon A. Ngelangel, Ma. Lourdes A. Tiambeng, Satisfaction in HER2 Testing among Medical Oncologists – Aiming for Multidisciplinary HER2 Testing in the Philippines , Acta Medica Philippina: Vol. 49 No. 2 (2015)
Henri S. Co, Marie Dione P. Sacdalan, Marc J. Lopez, Irisyl O. Real, Mark C. Ang, Edilberto V. Fragante, Manuel T. Roxas, Dennis L. Sacdalan, Andrew D. Dimacali, Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision in the Management of Locally Advanced Rectal Carcinoma – The PGH CRPoCan Study Group Experience 2008-2009 , Acta Medica Philippina: Vol. 49 No. 2 (2015)

Shape the Future of Philippine Medicine

Become a Peer Reviewer for Acta Medica Philippina — join a growing community of experts advancing Philippine medical research.

Apply Now

XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis

Authors

DOI:

Abstract

References

Most read articles by the same author(s)

Shape the Future of Philippine Medicine